Vitane Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Vitane Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress…

2006-08-23 Thane West, Maharashtra Active Unlisted Active Compliant
Share
Connect MCP
VP Vitane Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Vitane Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
86/100
Trust Score
Low Risk

Vitane Pharmaceuticals is assessed as Low Risk with a Trust Score of 86/100. Vitane Pharmaceuticals is an active private limited indian non-government company incorporated in 2006, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 15 Aug 2026 from the latest processed filings. Vitane Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Consolidated · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 65/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 3 open (27.96 cr) · 1 satisfied (35.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others3 48.0 cr
State Bank Of India1 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MOHAMMED HUSSAIN SADIQ 01234567 Director 01/04/2018 6 yrs Approved
MIRZA SAJJAD BAIG 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
2
Group entities
2
Capital events
10 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Intracell Therapeutics Private Limited Subsidiary Company 74.00%
Vitane Biologics Private Limited Subsidiary Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 75
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment75/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 27.96 cr already registered.
  • Compliance record supports lending.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
16 Oct 2024
Charge created
State Bank Of India - 22.00 cr
04 Nov 2022
Director ceased
VIJAY MUKESH THAKKAR
12 Apr 2021
Charge satisfied
Others
01 Mar 2019
Securities allotted
100383 Equity Shares - 10.04 Lakh raised
08 Feb 2019
Securities allotted
106749 Equity Shares - 10.67 Lakh raised
03 Jan 2019
Securities allotted
7119 Equity Shares - 71,190.00 raised
23 Dec 2018
Securities allotted
99360 Equity Shares - 9.94 Lakh raised
18 Apr 2018
Securities allotted
152445 Equity Shares - 45.73 Lakh raised
20 Feb 2018
Charge created
Others - 2.64 cr
19 Feb 2017
Securities allotted
155317 Equity Shares - 66.79 Lakh raised
20 Dec 2016
Charge created
Others - 35.00 cr
16 Mar 2016
Charge created
Others - 3.32 cr
09 Jul 2015
Securities allotted
2057866.00 Equity Shares - 2.06 cr raised
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 2 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 10 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Krunal Trading And Investment Pvt Ltd U51909GJ1989PTC012141 Ahmadabad City, Gujarat, India
Sea-Sky Marine Private Limited U61100MH2009PTC191860 Dombivli, Maharashtra, India
Magnum Strips And Tubes Private Limited U74899DL2000PTC108770 New Delhi, Delhi, India
Radhakrishna Agro Industries Private Limited U29253MH2015PTC262343 Jalgaon, Maharashtra, India
K.C. Edible Oils Private Limited U15142UP1992PTC014410 Uttar Pradesh, Uttar Pradesh, India
Neeraj Camellia Private Limited U01131CT1998PTC012992 Raipur, Chattisgarh, India
Chandra Polymer Private Limited U25209WB2010PTC152641 Kolkata, West Bengal, India
E Teenz U18100WB2007PLC115898 Howrah, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Vitane Pharmaceuticals before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Vitane Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Vitane Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Vitane Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Vitane Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Vitane Pharmaceuticals an active company?

Vitane Pharmaceuticals has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Vitane Pharmaceuticals financially healthy?

Vitane Pharmaceuticals has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Vitane Pharmaceuticals?

Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Vitane Pharmaceuticals?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Vitane Pharmaceuticals have loans or charges against its assets?

3 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Vitane Pharmaceuticals up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Vitane Pharmaceuticals?

Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.